SIGN UPLog In

General

Financials

People

Founders
Employee Profiles

Activity

Recent News
NeoPhore
NeoPhore
Company

Last deal

—

Amount

Series B

Stage

22.05.2024

Date

3

all rounds

$27.28M

Total amount

date founded

Financing round

General

About Company
NeoPhore develops small molecule immuno-oncology therapeutics that target genetic mechanisms to stimulate the immune system.

Industry

Sector :

Subsector :

founded date

01.11.2017

founders

Number of employees

1-10

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

NeoPhore's novel small molecule therapies focus on creating neoantigens, which can activate the immune system and potentially weaken tumor cells. By targeting components of the MMR pathway, which have been validated through clinical and preclinical studies, NeoPhore aims to discover and design effective medicines that will be part of the next generation of cancer immunotherapies.
Contacts

location

Cambridge, UK

Contact Email

Phone number

Website URL

http://www.neophore.com/

Social url

Legal Names

Legal name

Neophore Limited
Similar Companies
1000
Teon Therapeutics
Teon TherapeuticsTeon Therapeutics is developing small molecules to inhibit immunosuppressive cancer signaling pathways.
Teon Therapeutics

Teon Therapeutics

Teon Therapeutics is developing small molecules to inhibit immunosuppressive cancer signaling pathways.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Redwood City, CA, USA

total rounds

2

total raised

$37M
Cybrexa Therapeutics
Cybrexa TherapeuticsCybrexa Therapeutics is developing a new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.
Cybrexa Therapeutics

Cybrexa Therapeutics

Cybrexa Therapeutics is developing a new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

New Haven, CT, USA

total rounds

5

total raised

$44.4M
Replimune Group
Replimune GroupReplimune Group develops next-generation oncolytic immunotherapies to treat cancer.
Replimune Group

Replimune Group

Replimune Group develops next-generation oncolytic immunotherapies to treat cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Woburn, MA, USA

total rounds

9

total raised

$1.04B
Affimed
AffimedAffimed is a clinical-stage biopharmaceutical company focused on targeted cancer immunotherapies.
Affimed

Affimed

Affimed is a clinical-stage biopharmaceutical company focused on targeted cancer immunotherapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Heidelberg, Germany

total rounds

14

total raised

$513.93M

Financials

Funding Rounds
6
3

Number of Funding Rounds

$27.28M

Money Raised

Their latest funding was raised on 22.05.2024. Their latest investor Bristol Myers Squibb. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
22.05.2024
Series B
1
—
Bristol Myers Squibb
Bristol Myers Squibb
01.02.2024
Series B
8
$7.53M
Local Amount - GBP 9.6M
—
19.01.2023
Series B
5
$4.84M
Local Amount - GBP 6M
—
Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb is a pharmaceuticals and nutritional products company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Health Care, Manufacturing

Location

New York, NY, USA

total rounds

5

total raised

$23.58B

count Of Investments

77

count Of Exists

1
Co-Investors
Investors
11
3

Number of lead investors

11

Number of investors

Investor 
Lead 
Round 
Partners 
Bristol Myers Squibb
Bristol Myers Squibb
Yes
Series B
—
2invest
No
Series B
—
3B Future Health Fund
3B Future Health Fund
No
Series B
—
Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb is a pharmaceuticals and nutritional products company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Health Care, Manufacturing

Location

New York, NY, USA

total rounds

5

total raised

$23.58B

count Of Investments

77

count Of Exists

1

2invest

2invest AG acquires, manages, and sells investments in biotech, life science, and IT sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Biotechnology, Venture Capital

Location

Heidelberg, Germany

count Of Investments

3
3B Future Health Fund

3B Future Health Fund

Helsinn Investment Fund is a Luxembourg-based fund that focuses on early-stage investments in areas of high unmet patient need.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Munich, Germany

count Of Investments

30

count Of Exists

1

People

Founders
1
Alberto Bardelli
Alberto Bardelli

Alberto Bardelli

Alberto Bardelli is a professor at the University of Torino, He is also a Researcher and co-founder of Horizon Discovery, which is a successful British biotech company.

current job

NeoPhore
NeoPhore

organization founded

2
Alberto Bardelli

Alberto Bardelli

Employee Profiles
2
Stephen Over
Stephen Over

Stephen Over

Chief Financial Officer

Chief Financial Officer

Alberto Bardelli
Alberto Bardelli

Alberto Bardelli

Founder

Founder

Activity

Recent News
3
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month